JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 166 filers reported holding JUNO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $34,514,000 | -34.6% | 1,830,981 | +4.2% | 0.01% | -37.5% |
| Q3 2016 | $52,750,000 | -17.5% | 1,757,750 | +5.7% | 0.01% | -20.0% |
| Q2 2016 | $63,933,000 | +41.3% | 1,663,180 | +40.1% | 0.01% | +42.9% |
| Q1 2016 | $45,231,000 | -14.3% | 1,187,471 | -1.1% | 0.01% | -22.2% |
| Q4 2015 | $52,796,000 | +19.6% | 1,200,737 | +10.7% | 0.01% | +12.5% |
| Q3 2015 | $44,127,000 | +95.6% | 1,084,459 | +156.3% | 0.01% | +100.0% |
| Q2 2015 | $22,564,000 | -9.5% | 423,093 | +2.9% | 0.00% | 0.0% |
| Q1 2015 | $24,942,000 | +16309.2% | 411,170 | +14010.2% | 0.00% | – |
| Q4 2014 | $152,000 | – | 2,914 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |